Identification of ruxolitinib resistant mutations in Pro-B cells driven by a high-risk B-ALL JAK2-fusion

Charlotte EJ Downes; Barbara J McClure; Benjamin  Mayne; John B Bruning; Susan L Heatley; Chung H. Kok; Timothy P Hughes; David T Yeung; Deborah L White

Identification of ruxolitinib resistant mutations in Pro-B cells driven by a high-risk B-ALL JAK2-fusion

Charlotte EJ Downes, Barbara J McClure, Benjamin Mayne, John B Bruning, Susan L Heatley, Chung H. Kok, Timothy P Hughes, David T Yeung, Deborah L White

Research output: Contribution to conference › Poster

Abstract

We modelled and characterised rux resistance in JAK2r in vitro to enable development of therapeutic strategies to overcome or avert resistance in these high-risk patients.

Original language	English
Number of pages	1
Publication status	Published - 2018
Externally published	Yes
Event	2018 European Molecular Biology Laboratory (EMBL) Australia Postgraduate Symposium - Brisbane, Australia Duration: 28 Nov 2018 → …

Conference

Conference	2018 European Molecular Biology Laboratory (EMBL) Australia Postgraduate Symposium
Abbreviated title	2018 EMBL Australia Postgraduate Symposium
Country/Territory	Australia
City	Brisbane
Period	28/11/18 → …

Keywords

Ruxolitinib
resistant Mutations
B-ALL JAK2-fusion

Precision medicine approaches for JAK2-rearranged ALL: The efficacy of targeted therapies and molecular mechanisms of drug resistance
Toomes, C. (Associate Investigator), White, D. L. (Chief Investigator (Project Lead)), McClure, B. (Associate Investigator) & Bruning, J. B. (Associate Investigator)
12/03/18 → 31/12/22
Project: Research

Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia
Downes, C. E. J., McClure, B. J., Bruning, J. B., Page, E., Breen, J., Rehn, J., Yeung, D. T. & White, D. L., 10 Aug 2021, In: npj Precision Oncology. 5, 13 p., 75.
Research output: Contribution to journal › Article › peer-review

Open Access
File
21 Citations (Scopus)

58 Downloads (Pure)

Cite this

Downes, C. EJ., McClure, B. J., Mayne, B., Bruning, J. B., Heatley, S. L., Kok, C. H., Hughes, T. P., Yeung, D. T., & White, D. L. (2018). Identification of ruxolitinib resistant mutations in Pro-B cells driven by a high-risk B-ALL JAK2-fusion. Poster session presented at 2018 European Molecular Biology Laboratory (EMBL) Australia Postgraduate Symposium, Brisbane, Queensland, Australia.

@conference{e70504e2d30b46adbaa3af0e8e23be97,

title = "Identification of ruxolitinib resistant mutations in Pro-B cells driven by a high-risk B-ALL JAK2-fusion",

abstract = "We modelled and characterised rux resistance in JAK2r in vitro to enable development of therapeutic strategies to overcome or avert resistance in these high-risk patients.",

keywords = "Ruxolitinib, resistant Mutations, B-ALL JAK2-fusion",

author = "Downes, {Charlotte EJ} and McClure, {Barbara J} and Benjamin Mayne and Bruning, {John B} and Heatley, {Susan L} and Kok, {Chung H.} and Hughes, {Timothy P} and Yeung, {David T} and White, {Deborah L}",

year = "2018",

language = "English",

note = "2018 European Molecular Biology Laboratory (EMBL) Australia Postgraduate Symposium, 2018 EMBL Australia Postgraduate Symposium ; Conference date: 28-11-2018",

}

Identification of ruxolitinib resistant mutations in Pro-B cells driven by a high-risk B-ALL JAK2-fusion. / Downes, Charlotte EJ; McClure, Barbara J; Mayne, Benjamin et al.
2018. Poster session presented at 2018 European Molecular Biology Laboratory (EMBL) Australia Postgraduate Symposium, Brisbane, Queensland, Australia.

Research output: Contribution to conference › Poster

TY - CONF

T1 - Identification of ruxolitinib resistant mutations in Pro-B cells driven by a high-risk B-ALL JAK2-fusion

AU - Downes, Charlotte EJ

AU - McClure, Barbara J

AU - Mayne, Benjamin

AU - Bruning, John B

AU - Heatley, Susan L

AU - Kok, Chung H.

AU - Hughes, Timothy P

AU - Yeung, David T

AU - White, Deborah L

PY - 2018

Y1 - 2018

N2 - We modelled and characterised rux resistance in JAK2r in vitro to enable development of therapeutic strategies to overcome or avert resistance in these high-risk patients.

AB - We modelled and characterised rux resistance in JAK2r in vitro to enable development of therapeutic strategies to overcome or avert resistance in these high-risk patients.

KW - Ruxolitinib

KW - resistant Mutations

KW - B-ALL JAK2-fusion

M3 - Poster

T2 - 2018 European Molecular Biology Laboratory (EMBL) Australia Postgraduate Symposium

Y2 - 28 November 2018

ER -

Identification of ruxolitinib resistant mutations in Pro-B cells driven by a high-risk B-ALL JAK2-fusion

Abstract

Conference

Keywords

Fingerprint

Projects

Precision medicine approaches for JAK2-rearranged ALL: The efficacy of targeted therapies and molecular mechanisms of drug resistance

Research output

Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia

Cite this